Study Examines Genetics Impact on Statin Disposition and Response
Download Transcript, Episode 38 (81 KB)
Jonathan B. Wagner, DO
Length of Episode
Based on guidelines from the American Academy of Pediatrics (AAP), approximately 0.8 percent of adolescents 12 to 17 years old with dyslipidemia may qualify for pharmacological treatment.
That translates into approximately 200,000 adolescents who could be eligible for statin therapy.
With the increasing prevalence of overweight children, the incidence of clinically diagnosed coronary artery disease in young to middle-aged adults is expected to increase by 5 to 16 percent over the next two decades.
Jon Wagner, DO, is here to discuss how he is leading a research study looking at the liver specific protein transporter, OATP1B1, which is the major transporter of statins from the blood to the liver to better understand how children’s bodies distribute statins in the body.
Smith, Michael and Wagner, Jonathan B., "Study Examines Genetics Impact on Statin Disposition and Response" (2016). Transformational Pediatrics Podcast. 38.